Immix Biopharma, Inc.
IMMX
$2.12
$0.020.95%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.38% | -25.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 43.45% | -6.10% | |||
| Operating Income | -43.45% | 6.10% | |||
| Income Before Tax | -45.91% | 5.59% | |||
| Income Tax Expenses | -9.18% | -9.26% | |||
| Earnings from Continuing Operations | -45.79% | 5.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -45.79% | 5.60% | |||
| EBIT | -43.45% | 6.10% | |||
| EBITDA | -43.37% | 6.48% | |||
| EPS Basic | -44.47% | 6.08% | |||
| Normalized Basic EPS | -44.55% | 6.01% | |||
| EPS Diluted | -44.47% | 6.08% | |||
| Normalized Diluted EPS | -44.55% | 6.01% | |||
| Average Basic Shares Outstanding | 0.95% | 0.46% | |||
| Average Diluted Shares Outstanding | 0.95% | 0.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||